Funded Projects
Explore our currently funded projects. You may search with all three fields, then focus your results by applying any of the dropdown filters. After customizing your search, you may download results and even save your specific search for later.
Project # | Project Title | Research Focus Area | Research Program | Administering IC | Institution(s) | Investigator(s) | Location(s) | Year Awarded |
---|---|---|---|---|---|---|---|---|
1K99AT012658-01
Show Summary |
A Role for Peripheral NAAA-Regulated Lipid Signaling in the Control of Hyperalgesic Priming | Cross-Cutting Research | Training the Next Generation of Researchers in HEAL | NCCIH | UNIVERSITY OF CALIFORNIA-IRVINE | FOTIO, YANNICK | Irvine, CA | 2023 |
NOFO Title: HEAL Initiative Advanced Postdoctoral-to-Independent Career Transition Award in PAIN and SUD Research (K99/R00 Independent Clinical Trial Not Allowed)
NOFO Number: RFA-NS-22-022 Summary: Chronic pain remains a significant global heath challenge. Development of novel safe and effective treatments requires a deeper understanding of the molecular and cellular mechanisms that underlie the development of chronic pain. One protein that has been implicated in controlling the transition from acute to chronic pain is N-acylethanolamine acid amidase (NAAA). This project will evaluate how NAAA controls pain susceptibility after an acute insult and how this affects the emergence of chronic pain. |
||||||||
4R33DA057683-02
Show Summary |
Leveraging regulatory flexibility for methadone take-home dosing to improve retention in treatment for opioid use disorder: A stepped-wedge randomized trial to facilitate clinic level changes | Cross-Cutting Research | Translating Data 2 Action to Prevent Overdose | NIDA | NEW YORK UNIVERSITY SCHOOL OF MEDICINE | NEIGHBORS, CHARLES J (contact); BAO, YUHUA; RAMSEY, KELLY S | New York, NY | 2023 |
NOFO Title: HEAL Initiative: HEAL Data2Action Innovation Projects (R61/R33 Clinical Trial Optional)
NOFO Number: RFA-DA-22-051 |
||||||||
2SB1NS119103-04
Show Summary |
Novel non-narcotic analgesic for acute and chronic pain | Cross-Cutting Research | Small Business Programs | NINDS | SOUTH RAMPART PHARMA, LLC | NAISMITH, ROBERT | New Orleans, LA | 2023 |
NOFO Title: HEAL Commercialization Readiness Pilot (CRP) Program: Embedded Entrepreneurs for Small Businesses in Pain Management (SB1 Clinical Trial Not Allowed)
NOFO Number: PAR-23-069 |
||||||||
1K99AR083486-01
Show Summary |
Novel Models to Study Dorsal Root Ganglion Neurons in Knee Osteoarthritis Pain | Cross-Cutting Research | Training the Next Generation of Researchers in HEAL | NIAMS | STANFORD UNIVERSITY | BREWER, CHELSIE L | Stanford, CA | 2023 |
NOFO Title: HEAL Initiative Advanced Postdoctoral-to-Independent Career Transition Award in PAIN and SUD Research (K99/R00 Independent Clinical Trial Not Allowed)
NOFO Number: RFA-NS-22-022 Summary: Knee osteoarthritis (OA) is a frequent cause of disability and chronic pain. Treatment often relies on analgesics like opioids to manage OA pain, with all the associated risks; other approaches to treat OA are often invasive and inaccessible to patients. Therefore, novel analgesic strategies are needed to reduce the high burden of knee OA-induced pain. This project aims to study in detail and target the sensory neurons that drive OA pain to assist in the development of more effective pain therapeutics. |
||||||||
1R43HL167661-01A1
Show Summary |
Improving Analgesic Effectiveness and Safety with Proactive Precision Pain Management in Thoracic Surgical Patients with Lung Lesions | Cross-Cutting Research | Small Business Programs | NHLBI | OPALGENIX, INC. | PLUMP, STEVEN R (contact); SADHASIVAM, SENTHILKUMAR | Indianapolis, IN | 2023 |
NOFO Title: HEAL INITIATIVE: Development of Therapies and Technologies Directed at Enhanced Pain Management (R43/R44 - Clinical Trial Not Allowed)
NOFO Number: RFA-NS-20-011 |
||||||||
1K99AR083482-01
Show Summary |
Elucidating the Neuroimmune Mechanisms Underlying Pain and Inflammation in Autoimmune Arthritis | Cross-Cutting Research | Training the Next Generation of Researchers in HEAL | NIAMS | BOSTON CHILDREN'S HOSPITAL | JAIN, AAKANKSHA | Boston, MA | 2023 |
NOFO Title: HEAL Initiative Advanced Postdoctoral-to-Independent Career Transition Award in PAIN and SUD Research (K99/R00 Independent Clinical Trial Not Allowed)
NOFO Number: RFA-NS-22-022 Summary: Rheumatoid arthritis is an autoimmune disease characterized by episodes of joint inflammation and pain. There are currently no safe and effective treatments that achieve long-term remission of the condition or the associated pain. Many patients use opioid medications to manage the pain and are at increased risk of developing opioid use disorder; therefore, additional treatment options are needed. In rheumatoid arthritis, pain-triggering sensory neurons interact with immune cells in the joints. This project aims to dissect the neuroimmune crosstalk underlying pain and inflammation in arthritic joints and uncover novel therapeutic avenues for this painful condition. |
||||||||
1K01DA059641-01
Show Summary |
Adapting and Implementing a Chronic Disease Self-Management Program for Primary Care Patients with Opioid Use Disorder and Serious Mental Illness | Cross-Cutting Research | Training the Next Generation of Researchers in HEAL | NIDA | UNIVERSITY OF UTAH | SIANTZ, ELIZABETH | Salt Lake City, UT | 2023 |
NOFO Title: Career Development Awards in Implementation Science for Substance Use Prevention and Treatment (K01 - Clinical Trial Required)
NOFO Number: PAS-22-206 Summary: Many people with opioid use disorder (OUD) also have a serious mental illness and other chronic conditions, which can be difficult for individuals and primary care providers to manage. A chronic disease self-management program is an established health care model in which peers help to educate patients about their condition(s) and build problem-solving skills to manage their health. Such programs have been effective in other populations and settings, but they have not been adapted for primary care patients who have OUD and SMI. This project will adapt and test a chronic disease self-management program for this population to understand its feasibility, acceptability, impact, and how best to put such programs into place widely in primary care settings. |
||||||||
9SB1NS137964-04
Show Summary |
Advancing precision pain medicines to the clinic | Cross-Cutting Research | Small Business Programs | NINDS | NAVEGA THERAPEUTICS, INC. | MORENO, ANA MARIA (contact); ALEMAN GUILLEN, FERNANDO | San Diego, CA | 2023 |
NOFO Title: HEAL Commercialization Readiness Pilot (CRP) Program: Embedded Entrepreneurs for Small Businesses in Pain Management (SB1 Clinical Trial Not Allowed)
NOFO Number: PAR-23-069 |
||||||||
1K99NS134965-01
Show Summary |
Lymphocyte Antigen 6 (Ly6) Proteins: New Players in Chronic Pain | Cross-Cutting Research | Training the Next Generation of Researchers in HEAL | NINDS | NEW YORK UNIVERSITY | GOMEZ, KIMBERLY | New York, NY | 2023 |
NOFO Title: HEAL Initiative Advanced Postdoctoral-to-Independent Career Transition Award in PAIN and SUD Research to Promote Diversity (K99/R00 Independent Clinical Trial Not Allowed)
NOFO Number: RFA-NS-22-025 Summary: Neuropathic pain—a debilitating form of chronic pain affecting millions of people—responds poorly to current analgesic treatment approaches. By better understanding the cellular mechanisms and compounds involved in neuropathic pain, researchers will be able to develop more targeted therapeutic approaches. This project will investigate the role that two proteins—Ly6e and Lynx1—play in various processes involved in the development of neuropathic pain, such as the activity of pain-triggering sensory neurons, interactions between neurons and immune cells, and the activity of an ion channel that has been implicated in the generation of pain signals. |
||||||||
1R42NS132622-01
Show Summary |
Targeting TLR4-lipid rafts to prevent postoperative pain | Cross-Cutting Research | Small Business Programs | NINDS | RAFT PHARMACEUTICALS, LLC | DOUGHERTY, PATRICK M (contact); KOGAN, YAKOV | San Diego, CA | 2023 |
NOFO Title: HEAL Initiative: Development of Therapies and Technologies Directed at Enhanced Pain Management (R41/R42 Clinical Trial Not Allowed)
NOFO Number: RFA-NS-20-009 |
||||||||
1SB1AR083748-01
Show Summary |
Commercial Readiness in CTS Pain Management | Cross-Cutting Research | Small Business Programs | NIAMS | HIGHLAND INSTRUMENTS, INC. | WAGNER, TIMOTHY ANDREW (contact); DIPIETRO, LAURA | Cambridge, MA | 2023 |
NOFO Title: HEAL Commercialization Readiness Pilot (CRP) Program: Embedded Entrepreneurs for Small Businesses in Pain Management (SB1 Clinical Trial Not Allowed)
NOFO Number: PAR-23-069 |
||||||||
1K23DA058785-01
Show Summary |
Addressing the Readiness Gap: An eHealth Intervention to Increase Patient Motivation for Evidence-Based Chronic Pain Interventions and Reduced Opioid Reliance | Cross-Cutting Research | Training the Next Generation of Researchers in HEAL | NIDA | VIRGINIA COMMONWEALTH UNIVERSITY | CROUCH, TAYLOR BERENS | Richmond, VA | 2023 |
NOFO Title: Career Development Awards in Implementation Science for Substance Use Prevention and Treatment (K23 - Clinical Trial Required)
NOFO Number: PAS-22-207 Summary: Evidence-based behavioral treatments for pain are among the most effective and safe approaches, but they are underused, especially among patients taking opioids long-term. Despite known risks to long-term opioid therapy (including opioid use disorder and overdoses), patients may be reluctant to try something different to manage their pain. This project brings together two evidence-based behavior change interventions—motivational interviewing and contingency management—into an online format. The research will test whether web-based tools or mobile apps influence a patient’s willingness to consider using non-medication treatments for pain. The research will assess feasibility, acceptability to patients and providers, and broad-scale implementation. |
||||||||
2R44DE029369-02
Show Summary |
A Novel Opioid-Free Targeted Pain Control Method for Acute Post-Operative Localized Pain Related to Oral Surgical Procedures | Cross-Cutting Research | Small Business Programs | NINDS | REVBIO, INC. | JADIA, RAHUL (contact); KAY, GEORGE | Lowell, MA | 2023 |
NOFO Title: PHS 2022-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)
NOFO Number: PA-22-176 |
||||||||
1DP2HD112176-01
Show Summary |
Identifying Plasma Proteomic Profiles of Chronic Pain Development in Endometriosis From Adolescence to Adulthood | Cross-Cutting Research | Training the Next Generation of Researchers in HEAL | NICHD | BRIGHAM AND WOMEN'S HOSPITAL | SASAMOTO, NAOKO | Boston, MA | 2023 |
NOFO Title: Emergency Awards: HEAL Initiative- New Innovator Award (DP2 Clinical Trial Not Allowed)
NOFO Number: RFA-TR-22-013 Summary: Endometriosis is a gynecologic disorder characterized by severe pelvic pain, affecting 10% of reproductive aged women and adolescents worldwide. These individuals are at an increased risk for chronic opioid use, dependence, and overdose. Adolescents and young adults in particular are understudied in endometriosis research. This project will conduct a longitudinal study of adolescent endometriosis. The research will identify novel biomarkers and biological pathways involved in the transition of acute to chronic pain. The research aims to improve non-surgical endometriosis diagnosis, risk, and treatment. |
||||||||
1R43DA058614-01
Show Summary |
Combination Therapeutic for Chronic Opioid Use Disorder Relapse | Cross-Cutting Research | Small Business Programs | NIDA | APHIOS CORPORATION | CASTOR, TREVOR P | Woburn, MA | 2023 |
NOFO Title: PHS 2022-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)
NOFO Number: PA-22-176 Summary: Side effects from taking the opioid receptor blocker naltrexone make it difficult for patients to adhere to treatment with this medication for opioid use disorder. Cannabidiol (CBD), a bioactive ingredient of cannabis, is not an opioid and is non-psychoactive. Previous research shows that CBD blocks opioid-seeking behaviors, craving, and withdrawal. This project will develop tiny particles containing CBD and low-dose naltrexone. The research will determine if this combined version of CBD and naltrexone helps people stay in treatment and prevents relapse without problematic side effects. |
||||||||
1K01DA058750-01
Show Summary |
Leveraging mHealth to Increase Health Equity Among Black Individuals with OUD and Commonly Occurring Mental Health Disorders | Cross-Cutting Research | Training the Next Generation of Researchers in HEAL | NIDA | WASHINGTON UNIVERSITY | SZLYK, HANNAH | Saint Louis, MO | 2023 |
NOFO Title: HEAL Initiative: Career Development Awards in Implementation Science for Substance Use Prevention and Treatment (K01 - Clinical Trial Required)
NOFO Number: PAS-22-206 Summary: This project provides protected time for training and research activities that are required for an independent scientific career in the development, testing, and implementation of cutting-edge digital therapies and tools (such as smartphone apps and other web-based resources) that can promote health equity in treatment of opioid use disorder (OUD). The research will adapt and test digital overdose prevention and recovery support interventions for Black Americans with co-occurring OUD and mental illness. |
||||||||
1R44AR083337-01
Show Summary |
Development of a Regional Anesthesia Guidance System to Increase Patient Access to Opioid-Sparing Analgesia for Hip Fracture Pain | Cross-Cutting Research | Small Business Programs | NIAMS | RIVANNA MEDICAL, INC. | MAULDIN, FRANK WILLIAM | Charlottesville, VA | 2023 |
NOFO Title: HEAL INITIATIVE: Development of Therapies and Technologies Directed at Enhanced Pain Management (R43/R44 Clinical Trial Not Allowed)
NOFO Number: RFA-NS-23-006 Summary: Every year, more than 330,000 Americans are hospitalized for hip fractures. Rapid surgical intervention and pain treatment is critical to recover mobility and reduce other health complications. Ultrasound-guided regional anesthesia techniques are an effective alternative to opioid medication, but require specialized training for use in the emergency department. This project will develop and validate an easy-to-use ultrasound-based regional anesthesia guidance system, to ultimately improve access to non-opioid-pain treatment for hip fracture pain. |
||||||||
2R44DA048689-02
Show Summary |
Beacon-OUD: Behavioral Economic Screening Tool of Opioid Use Disorder (OUD) for Use in Clinical Practice | Cross-Cutting Research | Small Business Programs | NIDA | BEAM DIAGNOSTICS, INC. | SNIDER, SARAH EMILY | Roanoke, VA | 2023 |
NOFO Title: PHS 2021-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)
NOFO Number: PA-21-259 Summary: Current clinical screening measures for opioid misuse are underused and susceptible to bias. This project will develop Beacon-OUD, a digital opioid misuse assessment. The tool generates an automated, standardized score, preventing potential judgements related to patient’s status and circumstances, limiting stigma. The research will further advance Beacon-OUD into a commercial product for use both as a stand-alone tool and as an electronic health record-integrated solution to encourage objective opioid misuse screening in large health care systems. |
||||||||
2R44MD015912-03
Show Summary |
Clinical Optimization of Ultrasonic Drug Delivery Technologies for Underserved Minority U.S. Veterans in Chronic Pain | Cross-Cutting Research | Small Business Programs | NIMHD | ZETROZ SYSTEMS, LLC | LEWIS, GEORGE KENNETH | Trumbull, CT | 2023 |
NOFO Title: HEAL Initiative: Development of Therapies and Technologies Directed at Enhanced Pain Management (R43/R44 - Clinical Trial Required)
NOFO Number: RFA-NS-20-010 Summary: Osteoarthritis is one of the most common joint diseases affecting Americans. Osteoarthritis is particularly high among veterans with a service-related disability. This project will develop and refine a wireless ultrasound device that increases the penetration of over-the-counter pain medications into the body, which is expected to reduce pain. The research will conduct safety and clinical testing toward commercializing this technology. |
||||||||
1R61DA059169-01
Show Summary |
Leveraging Data to Action: Accelerating Emergency Department OUD Care by Improving Data Access and Infrastructure | Cross-Cutting Research | Translating Data 2 Action to Prevent Overdose | NIDA | YALE UNIVERSITY | VENKATESH, ARJUN KRISHNA (contact); HAWK, KATHRYN; TAYLOR, RICHARD ANDREW | New Haven, CO | 2023 |
NOFO Title: HEAL Initiative: HEAL Data2Action – Innovation and Acceleration Projects, Phased Awards (R61/R33, Clinical Trial Optional)
NOFO Number: RFA-DA-23-057 Summary: Emergency departments (EDs) are key settings for identifying and treating opioid use disorder (OUD), but EDs are underused for this purpose. This project aims to develop a data system that automates and integrates electronic health record and administrative data from EDs into the Clinical Emergency Department Registry, partnering with the American College of Emergency Physicians. The research will assess the digital readiness of ED systems before developing and deploying the enhanced ED OUD data infrastructure. This research aims to guide near-real time hospital quality improvement initiatives, toward development of a web-based, near-real time dashboard that can be used in EDs across the country. |
||||||||
1R41NS132625-01A1
Show Summary |
Opioid-Sparing Non-Surgical, Bioresorbable Nerve Stimulator for Pain Relief | Cross-Cutting Research | Small Business Programs | NINDS | VANISH THERAPEUTICS INC. | CUI, XINYAN TRACY | Mars, PA | 2023 |
NOFO Title: HEAL Initiative: Development of Therapies and Technologies Directed at Enhanced Pain Management (R41/R42 Clinical Trial Not Allowed)
NOFO Number: RFA-NS-23-007 Summary: Nerve stimulators are devices surgically implanted near a peripheral nerve or on the spinal cord that use electrical signals to reduce the perception of pain. Although these devices can provide effective pain relief to patients, many have high complication rates, resulting from the wire moving, breaking, not working, or the implantable battery pack or permanent wire causing new pain. This project will support the development and animal testing of a peripheral nerve stimulator to treat chronic pain which can be implanted without surgery. Once injected, the device will provide pain relief through electrical stimulation and then be safely degraded and resorbed by the body. |
||||||||
1R44DA058474-01
Show Summary |
Development of the OpiAID Strength Band Platform | Cross-Cutting Research | Small Business Programs | NIDA | OPIAID, INC. | REESER, DAVID (contact); MACQUEEN, DAVID ALDERSON; WASHINGTON, WENDY DONLIN | Wilmington, NC | 2023 |
NOFO Title: Developing Regulated Therapeutic and Diagnostic Solutions for Patients Affected by Opioid and/or Stimulants use Disorders (OUD/StUD) (R43/R44 - Clinical Trial Optional)
NOFO Number: RFA-DA-23-021 Summary: Although medications for opioid use disorder are effective and available, providers currently lack methods to monitor patients and thus inform improved dosing. This project will develop Strength Band Platform, an innovative artificial intelligence-based digital platform. The wearable device will collect patient physiological characteristics to detect relapse and withdrawal during treatment with medications for opioid use disorder in real-world settings. |
||||||||
3R01DA057630-01S1
Show Summary |
Predicting Fatal and Non-Fatal Overdose in Los Angeles County with Rapid Overdose Surveillance Dashboard to Target Street-Based Addiction Treatment and Harm Reduction Services | Cross-Cutting Research | Increasing Participant Diversity, Inclusion, and Engagement in HEAL Research | NIDA | UNIVERSITY OF CALIFORNIA LOS ANGELES | SHOVER, CHELSEA LEIGH (contact); GOODMAN, DAVID | Los Angeles, CA | 2023 |
NOFO Title: Research Supplements to Promote Diversity in Health-Related Research (Admin Supp - Clinical Trial Not Allowed)
NOFO Number: PA-21-071 Summary: The International Classification of Diseases 10th revision codes are insufficient to accurately identify individuals who use opioids and stimulants together. This project will search already collected electronic health record data using a computer program to identify people with polysubstance use and determine what health care they receive. The research will improve understanding of polysubstance use in a region of Los Angeles, California, with very high rates of overdoses involving fentanyl and stimulants. |
||||||||
1R44DA059302-01
Show Summary |
Development of an Opioid Sparing Therapeutic to Minimize Opioid Use Disorder and Tolerance in the Treatment of Pain | Cross-Cutting Research | Small Business Programs | NIDA | AMALGENT THERAPEUTICS, LLC | MEYN, MALCOLM A | Greenville, NC | 2023 |
NOFO Title: PHS 2022-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)
NOFO Number: PA-22-176 Summary: Managing the risks and benefits of opioid medications can be difficult. Although prescription opioids alleviate pain for some patients, serious adverse effects include opioid use disorder. There is a critical, unmet need for new technologies that significantly minimize the opioid doses needed for effective relief from moderate to severe pain. This project will develop a novel combination treatment containing a small amount of morphine along with pramipexole, a drug approved by the U.S. Food and Drug Administration for Parkinson’s disease and restless legs syndrome that reduces the reward-seeking behavior associated with opioids. The research will conduct safety studies to enable testing in human research participants. |
||||||||
1R43DA058430-01
Show Summary |
Predicting and Preventing Adverse Maternal and Child Outcomes of Opioid Use Disorder in Pregnancy | Cross-Cutting Research | Small Business Programs | NIDA | OPALGENIX, INC. | PLUMP, STEVEN R (contact); SADHASIVAM, SENTHILKUMAR | Carmel, IN | 2023 |
NOFO Title: Developing Regulated Therapeutic and Diagnostic Solutions for Patients Affected by Opioid and/or Stimulants use Disorders (OUD/StUD) (R43/R44 - Clinical Trial Optional)
NOFO Number: RFA-DA-23-021 Summary: There is an urgent and unmet clinical need for a reliable technology to prevent maternal opioid use relapse and neonatal opioid withdrawal syndrome (NOWS) in their infants. This project aims to assess risk for these outcomes based on individual genetic and clinical factors. The research will expand previous studies of genetic and clinical predictors of opioid-related adverse outcomes. The goal is to develop a risk predictor algorithm and software tool for use in an electronic health record, toward personalized risk assessment and prevention of maternal relapse and NOWS. |